Table 6.

Outcome of cardiac failure events in the ASPIRE, ENDEAVOR, and FOCUS trials

	ASPIRE		ENDEAVOR		FOCUS
	Carfilzomib (KRd)	Control (Rd)	Carfilzomib (Kd)	Control (Vd)	Carfilzomib (carfilzomib)	Control (BSC)
Patients with cardiac failure, n	25	16	38	13	12	7
Any-grade (standardized MedDRA query, narrow scope) cardiac failure outcome, n (%)
Resolved	15 (60.0)	6 (37.5)	14 (36.8)	8 (61.5)	6 (50.0)	1 (14.3)
Resolved with sequelae	2 (8)	0	0	0	0	0
Not resolved	10 (40)	10 (62.5)	23 (60.5)	5 (38.5)	6 (50)	5 (71.4)
Deaths	3 (12.0)	4 (25.0)	2 (5.3)	2 (15.4)	2 (16.7)	2 (28.6)